Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Deric Park

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentNeurology
AddressChicago IL 60637
Phone+1 (773) 7023510
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Deric Park is an expert in the diagnosis and treatment of brain and spine tumors, and its complications. In addition to both primary brain and metastatic cancers, he also specializes in rare conditions such as chordoma, meningioma, and hereditary cancer syndromes. He works collaboratively with the patient and family members to develop an individualized approach.

    Dr. Park’s research focuses on the development of more effective therapies that will benefit patients suffering from these conditions. His laboratory research efforts have directly been translated to clinical trials, and resulted in more than 50 peer-reviewed publications in scientific journals. He has held faculty positions at the University of Pittsburgh Cancer Institute, the University of Virginia, and the National Cancer Institute prior to being recruited to the University of Chicago. He is a recipient of the Merit and Career Development Awards from the American Society of Clinical Oncology, and a member of the Scientific Advisory Board for the Chordoma Foundation.


    Collapse Biography 
    Collapse education and training
    National Institute of Neurological Disorders and Stroke, NIH, MDFellowshipCell Biology
    Memorial Sloan Kettering Cancer Center, NYFellowshipNeuro-Oncology
    University of Chicago, ILResidency
    Evanston Hospital, ILInternship
    Loma Linda University, CAMD

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yuen CA, Rezania K, Park DM, Reder AT. Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy. 2021 01; 13(1):11-17. PMID: 33023359.
      View in: PubMed
    2. Yuen CA, Mastrianni J, Ali S, Pytel P, Park DM, Rezania K. An atypical presentation of primary central nervous system lymphoma: A case report. Medicine (Baltimore). 2020 Sep 18; 99(38):e22062. PMID: 32957327.
      View in: PubMed
    3. Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight. 2019 10 17; 4(20). PMID: 31536478.
      View in: PubMed
    4. Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, Giles AJ, Rich JN, Abounader R, Gilbert MR, Park DM. Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma. Cancer Res. 2019 10 15; 79(20):5218-5232. PMID: 31488423.
      View in: PubMed
    5. Cao X, Lu Y, Liu Y, Zhou Y, Song H, Zhang W, Davis D, Cui J, Hao S, Jung J, Wu Q, Park DM, Yang C. Combination of PARP inhibitor and temozolomide to suppress chordoma progression. J Mol Med (Berl). 2019 08; 97(8):1183-1193. PMID: 31201471.
      View in: PubMed
    6. Poser SW, Otto O, Arps-Forker C, Ge Y, Herbig M, Andree C, Gruetzmann K, Adasme MF, Stodolak S, Nikolakopoulou P, Park DM, Mcintyre A, Lesche M, Dahl A, Lennig P, Bornstein SR, Schroeck E, Klink B, Leker RR, Bickle M, Chrousos GP, Schroeder M, Cannistraci CV, Guck J, Androutsellis-Theotokis A. Controlling distinct signaling states in cultured cancer cells provides a new platform for drug discovery. FASEB J. 2019 08; 33(8):9235-9249. PMID: 31145643.
      View in: PubMed
    7. Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK. Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery. 2019 04 01; 84(4):945-953. PMID: 30189044.
      View in: PubMed
    8. Park DM, Overton KW, Jiao Y. The UzcRS two-component system in Caulobacter crescentus integrates regulatory input from diverse auxiliary regulators. Mol Microbiol. 2019 03; 111(3):678-699. PMID: 30536755.
      View in: PubMed
    9. Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R. Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. Cell Death Differ. 2019 Jan; 26(1):197. PMID: 29899381.
      View in: PubMed
    10. Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313. PMID: 30559168.
      View in: PubMed
    11. Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C, Park SH, Sung KS, Choi SA, Hwang J, Park DM, Kim SK, Park KJ, Kang SH, Oh SC, Ciechanover A, Lee YJ, Kim BY, Kwon YT. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2018 09; 19(9). PMID: 30185565.
      View in: PubMed
    12. Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018 06 11; 6(1):51. PMID: 29891009.
      View in: PubMed
    13. Feng J, Zhang Q, Li C, Zhou Y, Zhao S, Hong L, Song Q, Yu S, Hu C, Wang H, Mao C, Shepard MJ, Hao S, Dominah G, Sun M, Wan H, Park DM, Gilbert MR, Xu G, Zhuang Z, Zhang Y. Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3? in oncocytomas. J Pathol. 2018 07; 245(3):361-372. PMID: 29704241.
      View in: PubMed
    14. Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM. Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma. Neuro Oncol. 2018 05 18; 20(6):799-809. PMID: 29294092.
      View in: PubMed
    15. Gonçalves DPN, Park DM, Schmidt TL, Werner C. Modular peptide-functionalized gold nanorods for effective glioblastoma multicellular tumor spheroid targeting. Biomater Sci. 2018 May 01; 6(5):1140-1146. PMID: 29557480.
      View in: PubMed
    16. Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J. Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer. 2018 03 01; 18(1):239. PMID: 29490632.
      View in: PubMed
    17. Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM. LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation. Cancer Lett. 2018 02 28; 415:217-226. PMID: 29199006.
      View in: PubMed
    18. Park DM, Brewer A, Reed DW, Lammers LN, Jiao Y. Recovery of Rare Earth Elements from Low-Grade Feedstock Leachates Using Engineered Bacteria. Environ Sci Technol. 2017 Nov 21; 51(22):13471-13480. PMID: 28944666.
      View in: PubMed
    19. Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C, Park SH, Sung KS, Choi SA, Hwang J, Park DM, Kim SK, Park KJ, Kang SH, Oh SC, Ciechanover A, Lee YJ, Kim BY, Kwon YT. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2017 09; 18(9):1671. PMID: 28864661.
      View in: PubMed
    20. Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017 Jul 01; 19(7):887-896. PMID: 28339582.
      View in: PubMed
    21. Lee DH, Cheul Oh S, Giles AJ, Jung J, Gilbert MR, Park DM. Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1a in human glioma stem cells. Oncotarget. 2017 Jun 20; 8(25):40233-40245. PMID: 28410215.
      View in: PubMed
    22. Soeda A, Lathia J, Williams BJ, Wu Q, Gallagher J, Androutsellis-Theotokis A, Giles AJ, Yang C, Zhuang Z, Gilbert MR, Rich JN, Park DM. The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking. Oncotarget. 2017 May 16; 8(20):33316-33328. PMID: 28410196.
      View in: PubMed
    23. Park DM, Overton KW, Liou MJ, Jiao Y. Identification of a U/Zn/Cu responsive global regulatory two-component system in Caulobacter crescentus. Mol Microbiol. 2017 04; 104(1):46-64. PMID: 28035693.
      View in: PubMed
    24. Yoo YD, Lee DH, Cha-Molstad H, Kim H, Mun SR, Ji C, Park SH, Sung KS, Choi SA, Hwang J, Park DM, Kim SK, Park KJ, Kang SH, Oh SC, Ciechanover A, Lee YJ, Kim BY, Kwon YT. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Rep. 2017 01; 18(1):150-168. PMID: 27993939.
      View in: PubMed
    25. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579. PMID: 27826680.
      View in: PubMed
    26. Giles AJ, Chien CD, Reid CM, Fry TJ, Park DM, Kaplan RN, Gilbert MR. The functional interplay between systemic cancer and the hematopoietic stem cell niche. Pharmacol Ther. 2016 12; 168:53-60. PMID: 27595927.
      View in: PubMed
    27. Hao S, Feng J, Park DM, Gao Z. Glioma in Patients with Autosomal-Dominant Polycystic Kidney Disease. World Neurosurg. 2017 Feb; 98:885.e1-885.e5. PMID: 27565461.
      View in: PubMed
    28. Jung J, Gilbert MR, Park DM. Isolation and Propagation of Glioma Stem Cells from Acutely Resected Tumors. Methods Mol Biol. 2016; 1516:361-369. PMID: 27044042.
      View in: PubMed
    29. Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PLoS One. 2015; 10(8):e0134426. PMID: 26247786.
      View in: PubMed
    30. Yung MC, Park DM, Overton KW, Blow MJ, Hoover CA, Smit J, Murray SR, Ricci DP, Christen B, Bowman GR, Jiao Y. Transposon Mutagenesis Paired with Deep Sequencing of Caulobacter crescentus under Uranium Stress Reveals Genes Essential for Detoxification and Stress Tolerance. J Bacteriol. 2015 Oct; 197(19):3160-72. PMID: 26195598.
      View in: PubMed
    31. Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T, Park DM. CORRIGENDUM: The Evidence of Glioblastoma Heterogeneity. Sci Rep. 2015 May 26; 5:9630. PMID: 26010816.
      View in: PubMed
    32. Soeda A, Hara A, Kunisada T, Yoshimura S, Iwama T, Park DM. The evidence of glioblastoma heterogeneity. Sci Rep. 2015 Jan 27; 5:7979. PMID: 25623281.
      View in: PubMed
    33. Poser SW, Park DM, Androutsellis-Theotokis A. The STAT3-Ser/Hes3 signaling axis in cancer. Front Biosci (Landmark Ed). 2014 01 01; 19(4):718-26. PMID: 24389215.
      View in: PubMed
    34. Park DM, Akhtar MS, Ansari AZ, Landick R, Kiley PJ. The bacterial response regulator ArcA uses a diverse binding site architecture to regulate carbon oxidation globally. PLoS Genet. 2013; 9(10):e1003839. PMID: 24146625.
      View in: PubMed
    35. Poser SW, Park DM, Androutsellis-Theotokis A. The STAT3-Ser/Hes3 signaling axis: an emerging regulator of endogenous regeneration and cancer growth. Front Physiol. 2013; 4:273. PMID: 24101906.
      View in: PubMed
    36. Williams BJ, Raper DM, Godbout E, Bourne TD, Prevedello DM, Kassam AB, Park DM. Diagnosis and treatment of chordoma. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):726-31. PMID: 23744869.
      View in: PubMed
    37. Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH, Lee DH, Park DM, Kelley MJ, Sommer J, Austin CP. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013 Jul; 14(7):638-47. PMID: 23792643.
      View in: PubMed
    38. Park DM, Jung J, Masjkur J, Makrogkikas S, Ebermann D, Saha S, Rogliano R, Paolillo N, Pacioni S, McKay RD, Poser S, Androutsellis-Theotokis A. Hes3 regulates cell number in cultures from glioblastoma multiforme with stem cell characteristics. Sci Rep. 2013; 3:1095. PMID: 23393614.
      View in: PubMed
    39. Pacioni S, Rueger MA, Nisticò G, Bornstein SR, Park DM, McKay RD, Androutsellis-Theotokis A. Fast, potent pharmacological expansion of endogenous hes3+/sox2+ cells in the adult mouse and rat hippocampus. PLoS One. 2012; 7(12):e51630. PMID: 23251599.
      View in: PubMed
    40. Lu J, Ksendzovsky A, Yang C, Mehta GU, Yong RL, Weil RJ, Park DM, Mushlin HM, Fang X, Balgley BM, Lee DH, Lee CS, Lonser RR, Zhuang Z. CNTF receptor subunit a as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation. J Neurosurg. 2012 Dec; 117(6):1022-1031. PMID: 23061382.
      View in: PubMed
    41. Faraji AH, Engh JA, Horowitz M, Lunsford LD, Park DM. Multiple discrete aneurysmal subarachnoid hemorrhages during multimodality management of a hypothalamic glioma--case report. Clin Neurol Neurosurg. 2013 May; 115(5):632-5. PMID: 22795303.
      View in: PubMed
    42. Yang C, Iyer RR, Yu AC, Yong RL, Park DM, Weil RJ, Ikejiri B, Brady RO, Lonser RR, Zhuang Z. ß-Catenin signaling initiates the activation of astrocytes and its dysregulation contributes to the pathogenesis of astrocytomas. Proc Natl Acad Sci U S A. 2012 May 01; 109(18):6963-8. PMID: 22505738.
      View in: PubMed
    43. Williams BJ, Park DM, Sheehan JP. Bevacizumab used for the treatment of severe, refractory perilesional edema due to an arteriovenous malformation treated with stereotactic radiosurgery. J Neurosurg. 2012 May; 116(5):972-7. PMID: 22324417.
      View in: PubMed
    44. Park DM. Chordoma model. J Neurosurg. 2012 Apr; 116(4):799-800; discussion 800. PMID: 22283190.
      View in: PubMed
    45. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, Liu L, Eyler CE, Heddleston JM, Wu Q, Minhas S, Soeda A, Hoeppner DJ, Ravin R, McKay RD, McLendon RE, Corbeil D, Chenn A, Hjelmeland AB, Park DM, Rich JN. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2011 Sep 01; 2:e200. PMID: 21881602.
      View in: PubMed
    46. Sheehan JP, Popp B, Monteith S, Toulmin S, Tomlinson J, Martin J, Cifarelli CP, Lee DH, Park DM. Trans sodium crocetinate: functional neuroimaging studies in a hypoxic brain tumor. J Neurosurg. 2011 Oct; 115(4):749-53. PMID: 21682571.
      View in: PubMed
    47. Sheehan JP, Shaffrey ME, Gupta B, Larner J, Rich JN, Park DM. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010 Oct; 6(10):1591-601. PMID: 21062158.
      View in: PubMed
    48. Lu J, Zhuang Z, Song DK, Mehta GU, Ikejiri B, Mushlin H, Park DM, Lonser RR. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J Neurosurg. 2010 Aug; 113(2):225-33. PMID: 20001590.
      View in: PubMed
    49. Androutsellis-Theotokis A, Walbridge S, Park DM, Lonser RR, McKay RD. Cholera toxin regulates a signaling pathway critical for the expansion of neural stem cell cultures from the fetal and adult rodent brains. PLoS One. 2010 May 26; 5(5):e10841. PMID: 20520777.
      View in: PubMed
    50. Androutsellis-Theotokis A, Rueger MA, Park DM, Boyd JD, Padmanabhan R, Campanati L, Stewart CV, LeFranc Y, Plenz D, Walbridge S, Lonser RR, McKay RD. Angiogenic factors stimulate growth of adult neural stem cells. PLoS One. 2010 Feb 26; 5(2):e9414. PMID: 20195471.
      View in: PubMed
    51. Park DM, Sathornsumetee S, Rich JN. Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol. 2010 Feb; 7(2):75-7. PMID: 20118976.
      View in: PubMed
    52. Fang X, Balgley BM, Wang W, Park DM, Lee CS. Comparison of multidimensional shotgun technologies targeting tissue proteomics. Electrophoresis. 2009 Dec; 30(23):4063-70. PMID: 19960471.
      View in: PubMed
    53. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene. 2009 Nov 12; 28(45):3949-59. PMID: 19718046.
      View in: PubMed
    54. Androutsellis-Theotokis A, Rueger MA, Park DM, Mkhikian H, Korb E, Poser SW, Walbridge S, Munasinghe J, Koretsky AP, Lonser RR, McKay RD. Targeting neural precursors in the adult brain rescues injured dopamine neurons. Proc Natl Acad Sci U S A. 2009 Aug 11; 106(32):13570-5. PMID: 19628689.
      View in: PubMed
    55. Park DM, Rich JN. Biology of glioma cancer stem cells. Mol Cells. 2009 Jul 31; 28(1):7-12. PMID: 19655094.
      View in: PubMed
    56. Park DM, Shah DD, Egorin MJ, Beumer JH. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol. 2009 Jun; 93(2):279-83. PMID: 19125222.
      View in: PubMed
    57. Park DM, Yeaney GA, Hamilton RL, Mabold J, Urban N, Appleman L, Flickinger J, Lieberman F, Mintz A. Identifying Muir-Torre syndrome in a patient with glioblastoma multiforme. Neuro Oncol. 2009 Aug; 11(4):452-5. PMID: 19028998.
      View in: PubMed
    58. Androutsellis-Theotokis A, Murase S, Boyd JD, Park DM, Hoeppner DJ, Ravin R, McKay RD. Generating neurons from stem cells. Methods Mol Biol. 2008; 438:31-8. PMID: 18369747.
      View in: PubMed
    59. Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, Schiffman R, Merrill M, Walker ML, Park DM, Croteau D, Brady RO, Oldfield EH. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg. 2007 Jul; 107(1):190-7. PMID: 17639894.
      View in: PubMed
    60. Brouwers FM, Gläsker S, Nave AF, Vortmeyer AO, Lubensky I, Huang S, Abu-Asab MS, Eisenhofer G, Weil RJ, Park DM, Linehan WM, Pacak K, Zhuang Z. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocr Relat Cancer. 2007 Jun; 14(2):463-71. PMID: 17639059.
      View in: PubMed
    61. Park DM, Li J, Okamoto H, Akeju O, Kim SH, Lubensky I, Vortmeyer A, Dambrosia J, Weil RJ, Oldfield EH, Park JK, Zhuang Z. N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell Cycle. 2007 Feb 15; 6(4):467-70. PMID: 17312396.
      View in: PubMed
    62. Park DM, Zhuang Z, Chen L, Szerlip N, Maric I, Li J, Sohn T, Kim SH, Lubensky IA, Vortmeyer AO, Rodgers GP, Oldfield EH, Lonser RR. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 2007 Feb; 4(2):e60. PMID: 17298169.
      View in: PubMed
    63. Lonser RR, Schiffman R, Robison RA, Butman JA, Quezado Z, Walker ML, Morrison PF, Walbridge S, Murray GJ, Park DM, Brady RO, Oldfield EH. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology. 2007 Jan 23; 68(4):254-61. PMID: 17065591.
      View in: PubMed
    64. Li J, Zhuang Z, Okamoto H, Vortmeyer AO, Park DM, Furuta M, Lee YS, Oldfield EH, Zeng W, Weil RJ. Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology. 2006 Mar 14; 66(5):733-6. PMID: 16534112.
      View in: PubMed
    65. Lubensky IA, Vortmeyer AO, Kim S, Lonser RR, Park DM, Ikejiri B, Li J, Okamoto H, Walbridge S, Ryschkewitsch C, Major E, Oldfield EH, Zhuang Z. Identification of tumor precursor cells in the brains of primates with radiation-induced de novo glioblastoma multiforme. Cell Cycle. 2006 Feb; 5(4):452-6. PMID: 16479164.
      View in: PubMed
    66. Prat E, Tomaru U, Sabater L, Park DM, Granger R, Kruse N, Ohayon JM, Bettinotti MP, Martin R. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol. 2005 Oct; 167(1-2):108-19. PMID: 16111772.
      View in: PubMed
    67. Park DM, DeAngelis LM. Delayed infection of the Ommaya reservoir. Neurology. 2002 Sep 24; 59(6):956-7. PMID: 12297592.
      View in: PubMed
    68. Park DM, Abrey LE. Pharmacotherapy of primary CNS lymphoma. Expert Opin Pharmacother. 2002 Jan; 3(1):39-49. PMID: 11772332.
      View in: PubMed
    69. Witman AB, Park DM, Hardin SB. How do patients want physicians to handle mistakes? A survey of internal medicine patients in an academic setting. Arch Intern Med. 1996 Dec 9-23; 156(22):2565-9. PMID: 8951299.
      View in: PubMed
    Park's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (390) concept(s)
    _
    Co-Authors Expand Description
    See all (4) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _